info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

US Melanoma Companies

Pioneering advancements in dermatological care, US Melanoma companies specialize in research, treatment, and patient support. Focused on combating melanoma, these organizations contribute to the understanding and management of skin cancer, offering innovative therapies that aim to improve outcomes and enhance the lives of those affected.

US Melanoma Key Companies

 

Latest US Melanoma Companies Update


Merck Sharp & Dohme (MSD) Receives FDA Approval for KEYTRUDA® (pembrolizumab) in Combination with YERVOY® (ipilimumab) for First-Line Treatment of Advanced/Unresectable Stage III Melanoma: This January 2024 approval expands treatment options for patients with advanced melanoma, offering a potentially more effective combination therapy.


Bristol-Myers Squibb (BMS) Announces Positive Phase 3 Results for Opdivo® (nivolumab) in Combination with RELIBRANT® (nivolumab + ipilimumab) for Adjuvant Treatment of Stage


III Melanoma: December 2023 development suggests the potential of this combination therapy to improve long-term survival outcomes in high-risk Stage III melanoma patients.


IO Biotech Partners with Regeneron to Develop Novel Immunotherapy for Melanoma: January 2024 collaboration combines expertise to accelerate the development of IOB-C100, a potential new class of immunotherapy targeting the LAG-3 immune checkpoint.


List of US Melanoma Key Companies in the Market



  • Amgen Inc.

  • Bristol-Myers Squibb

  • Eisai Co. Ltd.

  • Hoffmann-La Roche Ltd.

  • Genentech Inc. Janssen Biotech Inc.

  • and Novartis International AG. Pfizer

  • Vical

  • Ziopharm


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.